Boehringer Ingelheim and Eli Lilly and Company Announced Jentadueto tablets Receive Approval for the Treatment of Adults with Type 2 Diabetes in Europe
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the receipt of Marketing Authorization from the European Commission for Jentadueto® (linagliptin/metformin hydrochloride) tablets, a medicine combining the DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta® tablets, marketed under the trade name Trajenta® in Europe) and metformin in a single tablet taken twice daily.
The European Commission has approved JENTADUETO for use alongside diet and exercise to improve glycemic control in adults with type 2 diabetes who are inadequately controlled on their maximally tolerated dose of metformin alone, metformin and a sulfonylurea, or those already being treated with the combination of linagliptin and metformin.1 It may be used with a sulfonylurea, as well. JENTADUETO provides a new, single-tablet treatment option, taken twice daily, for adults with type 2 diabetes who need to improve control of their blood glucose.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.